Short answer
Baxter International (BAX) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2.7B (up 2.9% year over year) with net income of −$15M.
Q1 2026 key financials · XBRL
- Revenue
- $2.7B
- +2.9% YoY
- Net income
- −$15M
- −111.9% YoY
- Operating margin
- 2.4%
- Gross margin
- 33.0%
- EPS (diluted)
- −$0.03
- −112.0% YoY
Source: XBRL data from the Baxter International (BAX) Q1 2026 10-Q on SEC EDGAR. USD.
Baxter International Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2.701B, up 3% YoY from $2.625B; organic sales declined 1%
- Net loss $15M vs $126M profit YoY; special items reduced income by $205M vs $194M
- Best segment: Pharmaceuticals, $621M revenue, up 7%; Drug Compounding rose 30% to $320M
- Worst product line: Injectables & Anesthesia, $301M revenue, down 10% from $335M
- Headwinds: Novum LVP hold, supply constraints, tariffs, inflation, and weaker hospital capital spending risk
Risk Factors
- No material changes to risk factors disclosed in Baxter’s 2025 Annual Report
- Carried-forward regulatory risk: compliance obligations under applicable securities laws
- Carried-forward operational risk: Baxter’s previously disclosed business and supply-chain exposures
- Carried-forward financial risk: liquidity, debt, currency, and concentration exposures remain unchanged from the 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Baxter International quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.